Datasheet

生物学的記述

Specificity	N myc interactor/NMI Antibody [B12H19] detects endogenous levels of total N myc interactor/NMI protein.
Background	N‑Myc interactor (NMI) is a co-regulatory protein originally identified through its physical association with Myc family oncoproteins and STAT transcription factors and is now recognized as a cytokine‑inducible modulator of oncogenic and innate immune signaling that acts both intracellularly and, in some contexts, as a secreted damage‑associated signal. The protein lacks obvious enzymatic domains and instead contains coiled‑coil and helical regions that support hetero‑oligomeric complex formation with basic helix–loop–helix–leucine zipper transcription factors such as N‑Myc and c‑Myc and with STATs, including STAT1 and STAT5, and these interactions position NMI as a scaffold that influences transcriptional output rather than DNA‑binding specificity. NMI binds multiple STAT family members (all except STAT2) and enhances STAT‑dependent transcription in response to IL‑2 and IFN‑γ by promoting recruitment of CBP/p300 coactivators to STAT1‑ and STAT5‑containing complexes, thereby amplifying cytokine‑driven gene expression programs involved in growth control, differentiation, and immune effector function. In parallel, NMI associates with Myc proteins and with BRCA1 in a tricomplex that can repress c‑Myc‑induced hTERT promoter activity in breast cancer, and it modulates Myc‑dependent transcriptional programs that control proliferation, apoptosis, and telomerase regulation, linking NMI abundance and localization to Myc oncogenic potency. NMI also participates in Wnt/β‑catenin signaling control: enforced NMI expression upregulates the Wnt antagonist DKK1, destabilizes β‑catenin, reduces expression of β‑catenin target genes such as cyclin D1, and retards tumor cell growth, indicating that NMI can antagonize pro‑proliferative Wnt signaling and intersect with Myc‑driven networks through shared target pathways. In innate immune regulation, NMI is induced by interferons and forms a complex with IFI35 that stabilizes IFI35 and shapes type I interferon and NF‑κB outputs; ubiquitination of the NMI–IFI35 complex by TRIM21 and NMI‑dependent degradation of IRF7 attenuate virus‑triggered IFN‑β production, while secreted NMI released from injured or activated macrophages binds TLR4 on neighboring macrophages to activate NF‑κB and drive production of pro‑inflammatory cytokines, which defines NMI as both an intracellular signaling regulator and an extracellular DAMP in inflammatory microenvironments.

Specificity

N myc interactor/NMI Antibody [B12H19] detects endogenous levels of total N myc interactor/NMI protein.

Background

N‑Myc interactor (NMI) is a co-regulatory protein originally identified through its physical association with Myc family oncoproteins and STAT transcription factors and is now recognized as a cytokine‑inducible modulator of oncogenic and innate immune signaling that acts both intracellularly and, in some contexts, as a secreted damage‑associated signal. The protein lacks obvious enzymatic domains and instead contains coiled‑coil and helical regions that support hetero‑oligomeric complex formation with basic helix–loop–helix–leucine zipper transcription factors such as N‑Myc and c‑Myc and with STATs, including STAT1 and STAT5, and these interactions position NMI as a scaffold that influences transcriptional output rather than DNA‑binding specificity. NMI binds multiple STAT family members (all except STAT2) and enhances STAT‑dependent transcription in response to IL‑2 and IFN‑γ by promoting recruitment of CBP/p300 coactivators to STAT1‑ and STAT5‑containing complexes, thereby amplifying cytokine‑driven gene expression programs involved in growth control, differentiation, and immune effector function. In parallel, NMI associates with Myc proteins and with BRCA1 in a tricomplex that can repress c‑Myc‑induced hTERT promoter activity in breast cancer, and it modulates Myc‑dependent transcriptional programs that control proliferation, apoptosis, and telomerase regulation, linking NMI abundance and localization to Myc oncogenic potency. NMI also participates in Wnt/β‑catenin signaling control: enforced NMI expression upregulates the Wnt antagonist DKK1, destabilizes β‑catenin, reduces expression of β‑catenin target genes such as cyclin D1, and retards tumor cell growth, indicating that NMI can antagonize pro‑proliferative Wnt signaling and intersect with Myc‑driven networks through shared target pathways. In innate immune regulation, NMI is induced by interferons and forms a complex with IFI35 that stabilizes IFI35 and shapes type I interferon and NF‑κB outputs; ubiquitination of the NMI–IFI35 complex by TRIM21 and NMI‑dependent degradation of IRF7 attenuate virus‑triggered IFN‑β production, while secreted NMI released from injured or activated macrophages binds TLR4 on neighboring macrophages to activate NF‑κB and drive production of pro‑inflammatory cytokines, which defines NMI as both an intracellular signaling regulator and an extracellular DAMP in inflammatory microenvironments.

使用情報

Application

WB, IP, IHC, IF

Dilution

WB	IP	IHC	IF
1:10000-1:50000	1:40-1:60	1:50	1:100

Reactivity

Human

Source

Rabbit Monoclonal Antibody

MW

35 kDa

Storage Buffer

PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage
(from the date of receipt)

-20°C (avoid freeze-thaw cycles), 2 years

プロトコール

References

https://pubmed.ncbi.nlm.nih.gov/26874464/
https://pubmed.ncbi.nlm.nih.gov/19358268/

N myc interactor/NMI Antibody [B12H19]

生物学的記述

使用情報

References

Application Data